Polverino, Eva
Eva Polverino researcher
VIAF ID: 313289978 (Personal)
Permalink: http://viaf.org/viaf/313289978
Preferred Forms
- 100 0 _ ‡a Eva Polverino ‡c researcher
- 200 _ 1 ‡a Polverino ‡b , Eva
- 200 _ | ‡a Polverino ‡b Eva
- 100 1 _ ‡a Polverino, Eva
- 100 1 _ ‡a Polverino, Eva
- 100 1 _ ‡a Polverino, Eva
-
4xx's: Alternate Name Forms (1)
Works
Title | Sources |
---|---|
Acute exacerbations of COPD: risk factors for failure and relapse | |
Addition of hyaluronic acid improves tolerance to 7% hypertonic saline solution in bronchiectasis patients | |
Assessment of ultrasound acoustic artifacts in patients with acute dyspnea: a multicenter study | |
Atypical Mycobacteria in Bronchiectasis. When do we Treat it? | |
Author's response to 'CAP and HCAP are different? An unresolved question' | |
The best of respiratory infections from the 2015 European Respiratory Society International Congress | |
The BRICS | |
The BRICS (Bronchiectasis Radiologically Indexed CT Score): A Multicenter Study Score for Use in Idiopathic and Postinfective Bronchiectasis. | |
Bronchiectasis in severe asthma: a distinct phenotype? | |
Characterisation of the "Frequent Exacerbator Phenotype" in Bronchiectasis. | |
Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome. | |
Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations. | |
Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network. | |
Current perspective of the HCAP problem: is it CAP or is it HAP? | |
The EMBARC European Bronchiectasis Registry: protocol for an international observational study | |
Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity | |
The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration. | |
European Respiratory Society guidelines for the management of adult bronchiectasis | |
Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study. | |
Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age | |
Immunofluorescence Analysis as a Diagnostic Tool in a Spanish Cohort of Patients with Suspected Primary Ciliary Dyskinesia | |
The Importance of Phenotyping Bronchiectasis. | |
The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. | |
Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. | |
Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia | |
Macrolides, mucoactive drugs and adherence for the management of bronchiectasis. | |
Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case-control study | |
Multiple inert gases elimination technique (MIGET) and gas exchange in obstructive respiratory diseases : tesi di dottorato in fisiopatologia e clinica dell'apparato cardiovascolare e respiratorio : corso 2003-2005 / Eva Polverino ; tutor: Carlo Giuntini ; Fisiopatologia respiratoria, Dipartimento cardio-toracico, Ospedale di Cisanello, Università di Pisa, Ospedale di Cisanello-Pisa | |
Nursing home-acquired pneumonia: a 10 year single-centre experience. | |
The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions | |
Patient participation in ERS guidelines and research projects: the EMBARC experience | |
Patients' characterization, hospital course and clinical outcomes in five Italian respiratory intensive care units. | |
Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis | |
Pneumonic and non-pneumonic exacerbations in bronchiectasis: clinical and microbiological differences. | |
Pulmonary complications of HIV, [2014]: | |
Pulmonary disease by non-tuberculous mycobacteria - clinical management, unmet needs and future perspectives. | |
Pulmonary exacerbations in patients with primary ciliary dyskinesia: an expert consensus definition for use in clinical trials | |
The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis. | |
Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations | |
The Role of Neutrophil Elastase Inhibitors in Lung Diseases | |
Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients. | |
Severe Community‐Acquired Pneumonia: Validation of the Infectious Diseases Society of America/American Thoracic Society Guidelines to Predict an Intensive Care Unit Admission | |
Sex bias in diagnostic delay in bronchiectasis: An analysis of the Spanish Historical Registry of Bronchiectasis. | |
Short-term effects of three slow expiratory airway clearance techniques in patients with bronchiectasis: a randomised crossover trial | |
Standardised classification of the aetiology of bronchiectasis using an objective algorithm. | |
Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome | |
Thrombocytosis is a marker of poor outcome in community-acquired pneumonia | |
Urban residence is associated with bronchial hyperresponsiveness in Italian general population samples. | |
Validation of a Spanish version of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. | |
VAP surveillance: role of non-quantitative culture of endotracheal aspirates (NQC-ETA) | |
A worldwide perspective of nursing home-acquired pneumonia compared with community-acquired pneumonia. |